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Abstract. In recent years, numerous countries around the world have continually devoted 
substantial efforts to the biotechnology industry. Despite its endeavors over two decades, 
Taiwan’s biotechnology industry has not yet made any remarkable achievements. In this 
study, influential factors of cooperation in the biotechnology industry are discussed from 
the perspectives of cluster cooperation and interaction. Using the analytic hierarchy process 
and quantitative results obtained from in-depth expert interview questionnaires, the weights 
of various influential factors are investigated and analyzed, which could provide a reference 
for future research and resource allocations. The influential factors of cluster cooperation in 
Taiwan’s biotechnology industry can be categorized into four major factors and sixteen 
sub-factors. The results indicate that among all of the factors that impact cluster 
cooperation in the biotechnology industry, “enterprise innovation ability” is the most 
critical. The innovation capacity of cooperative partners is always considered a priority in 
cluster cooperation among enterprises, whereas research and development (R&D), 
personnel quality, and the R&D environment are the most crucial sub-factors within the 
primary dimension of enterprise innovation ability. This finding is consistent with the fact 
that a biotechnology product is closely bound to innovative R&D, from its initial 
development stage to the eventual clinical launch. Factors of secondary importance include 
business management ability and government resource utilization, which suggests that the 
principal activities associated with cluster cooperation in the biotechnology industry depend 
heavily on an enterprise’s business management ability and are inextricably linked to 
government resource utilization.  
Keywords. Biotechnology industry, Cluster cooperation, Taiwan, Analytic hierarchy 
process (AHP). 
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1. Introduction 
ecause biotechnology is highly technological, has great market potential, 
provides high added value, and is characterized by low levels of pollution 
and energy dependency, and because personalized medical demands are 
rapidly increasing due to population growth and aging, countries worldwide have 
adopted biotechnology as a state policy to improve people’s health and well-being 
and have made substantial investments in this industry, leading to a powerful trend 
of biotechnology development. Globally, the United States has the most developed 
biotechnology industry, which is characterized by large capital investments in and 
assiduous management of R&D in the bioscience, biomedicine, and biotechnology 
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fields. In the private sector, people’s enthusiasm for and active investments in 
biotechnology are also remarkable. In addition to the highly stable infrastructure, 
relevant supporting measures have facilitated the increase in biotechnology 
companies’ initial public offerings. The overall performance of this industry, 
including the number of biotechnology companies and product programs approved 
by the Food and Drug Administration, makes the biotechnology industry in the 
United States an undisputed leader in this field. 
In contrast to advanced Euro-American countries, Taiwan is considered a 
follower, rather than a leader, in terms of the key techniques adopted by its protein 
pharmaceutical industry. For Taiwan to be ranked among the leading countries in 
biotechnology, its protein pharmaceutical development musttake advantage of the 
government’s comprehensive goal-oriented R&D plans. Taiwan made a delayed 
entry into the field of biotechnology; indeed, this field was not included among the 
major future scientific and technical projects promoted by large-scale R&D plans 
until the 1980s. Since then, biotechnology-associated departments and research 
institutes have been established to nurture biotechnology talents and accumulate 
energy for Taiwan’s biotechnology R&D. A comprehensive set of promotional 
measures have been implemented, including techniques, talents, capital, legislation, 
clinical trials, technology transfers, and incubator zones, providing a superior 
environment for biotechnology development. Today, the infrastructure required for 
biotechnology development has been established. The R&D energy of research 
institutes can play a role in biotechnology development through the mechanisms of 
technology transfer and incubation. Relevant techniques developed by upper- and 
middle-reach enterprises can be smoothly transferred to lower-reach enterprises for 
commercial exploration and to further promote technology in the global market. 
Organizations that are primarily responsible for technology promotion include 
universities and central research institutes, which conduct fundamental innovation 
research; the Department of Health, which designs and implements regulations and 
policies; the Ministry of Economic Affairs (MOEA), which commercializes and 
industrializes technologyand encourages investment; and certain specialized 
organizations that promote particular technologies, such as the Council of 
Agriculture. 
To investigate the structure of biotechnology industry development, the 
characteristics of the biotechnology industry that distinguish it from general 
industry are considered, including the long development processand the significant 
business management challenges encountered from early R&D to product launch. 
In addition, influential factors are discussed from the perspective of the supply of 
and demand for cluster cooperation in the biotechnology industry.  
In previous research, the performance of the biotechnology industry is mainly 
explored from the perspective of government policies. A limited number of studies 
have discussed the relationship between biotechnology industry development and 
the factors that influence this development based on biotechnology industry cluster 
cooperation. This research aims to use quantitative data to explore the correlation, 
importance, and disadvantages of factors that impact the development of the 
biotechnology industry for the purpose of providing a reference to aid 
decisionmaking by relevant organizations. The objectives of this study are to 
investigate the influential factors of cluster cooperation in Taiwan’s biotechnology 
industry, to analyze the mutual impacts of these factors using the analytic hierarchy 
process (AHP), and to identify the critical factors in the government’s 
decisionmaking. 
 
2. Literature review 
2.1.The status quo of the biotechnology industry 
To stimulate the development of biotechnology- and pharmaceutical-related 
industries and to improve people’s health and social well-being, Taiwan’s 
Industrial Development Bureau, MOEA, uses a relatively broad definition of 
biotechnology and pharmaceuticals. This definition encompasses three major 
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sections: the pharmaceutical industry, the medical device industry, and the applied 
biotechnology industry. The pharmaceutical industry essentially comprises 
pharmaceuticals, including Western medicines, biologics, traditional Chinese 
medicines, and active pharmaceutical ingredients. The medical device industry is 
divided into various sections based on function and application: diagnostic and 
monitoring; surgical and therapeutic; assistive and compensation; in-vitro 
diagnostics; prevention and health promotion; and miscellaneous. The applied 
biotechnology industry mainly involves product R&D and manufacturing using 
biotechnology but also includes the provision of services for pharmaceutical 
exploration. Its industrial projects include agricultural, food, specialty, 
environmental, and contact biotechnology projects. The breakdown of Taiwan’s 
biotechnology industry from 2013 to 2014 is presented in Table 1. 
 
Table 1. Breakdown of Taiwan’s biotechnology industry from 2013 – 2014 (Unit: NTD 
(100 million) 
Industry 
Applied 
biotechnology 
industry 
Pharmaceutical 
industry 
Medical device 
industry Total 
Year  2013 2014 2013 2014 2013 2014 2013 2014 
Revenue 782 822 824 832 1,163 1,232 2,769 2,886 
Number of 
enterprises 
490 500 350 350 761 781 1,601 1,631 
Number of 
employees 
17,540 18,340 19,000 19,000 35,040 36,429 71,580 73,769 
Export value 299 312 196 197 484 513 979 1,022 
Import value 495 500 992 999 605 615 2,092 2,114 
Domestic sales: 
export sales 
62:38 62:38 76:24 76:24 58:42 58:42 65:35 65:35 
Demand of 
domestic market 
978 1,010 1,620 1,634 1,284 1,334 3,882 3,978 
Data source: Medical and Pharmaceutical Industry Technology and Development Center, 
Biotechnology and Pharmaceutical Industries Promotion Office, MOEA, 2015. 
 
2.2. Biotechnology industry 
The former Vice President of the United States, Al Gore, who won the Nobel 
Peace Prize in 2007, described in his book “The Future: Six Drivers of Global 
Change” the emergence of a new set of revolutionary and powerful biological, 
biochemical, genetic, and material science technologies launched by scientists that 
would allow us to observe, explore, describe, modify, and control biological cells 
and enable the genetic information of living cells to flow between each other, even 
across species boundaries. Creating a new body part with three-dimensional (3D) 
printing could satisfy people’s unmet medical needs. Protein pharmaceuticals are 
competitively developed to cure diseases, including diabetes, cardiovascular 
diseases, cancer and rare diseases. Nanoscale-precision robot techniques that can 
control the measurement of brain waves and integrate the applications of the 
human brain, computer interface, material science, and nanotechnology could 
transform a human being’s life, from birth until death. 
Given the need toachieve sustainable development, biotechnology has already 
been universally regarded as a critical field forsolving various global challenges, 
such as emerging infectious diseases, inadequate food supply, limited water 
resources, climate extremalization, and the need for preventive medicine, in 
addition to enhancing environmental consciousness. In the future, new medical 
demand situations are expected in Taiwan, which may involve prospective 
medicine and integrated medical services using big data. For example, organ 
transplantation using 3D printing technologies, the treatment of disease with 
newlydeveloped protein pharmaceuticals, early predictionsregarding physical 
health using big data analysis, the provision of preventive medical services based 
on area warnings of potential infectious diseases, and synchronous transmission of 
individual medical diagnostic information to hospitals before a first-aid patient 
arrives. In addition, as the population ages and birth rates decline, the medical and 
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pharmaceutical requirements triggered by the relevant age care are gradually 
increasing, leaving no time to improveor develop the biotechnology industry. 
Applications of biotechnology tend to be diversified, ranging from food supply 
to the exploration of the human lifecycle, including birth, aging, illness, and death. 
In particular, the occurrence, treatment, and prevention of human diseases are an 
important focus of biotechnology. Numerous countries have proposed strategies 
and plans for biotechnology industry development. The biotechnology 
development guidelines proposed by various countries are described below; 
notably, all of them involve cluster cooperation. 
1) The United States is a pioneer in the global biotechnology industry. Its first 
biotechnology company, Genentech, was established in 1976 and has a 41-year 
history. Genentech flourished due to the United States’ early policies to promote 
the biotechnology industry, including the federal government’s massive investment 
budget for the biotechnology industry; strict biotechnology regulatory mechanisms; 
laws and incentive measures designed to promote technology transfer and 
commercialization; local governments’efforts to attract the entry of new 
enterprises; and a liberalized market economy. Among these policies, the 
investment by the federal government, local governments’ efforts to attract new 
entry, and the laws and incentive measures to promote technology transfer and 
commercialization involve cluster cooperation among biotechnology enterprises. 
Enterprises increase R&D energy through cluster cooperation, which ensures that 
their demands are taken seriously and assists them in obtaining solutions. 
2) Talavyria et al., (2015) suggested to the German Bioeconomy Council 
(GBC), which had conducted a bioeconomy analysis, that the German government 
should focus on the following issues to develop the biotechnology industry: a) 
breaking traditional barriers and strengthening communication between science, 
commerce, and politics; b) creating bioeconomy R&D funds to reward 
performance benchmarks; c) implementing regulations that supported the 
biotechnology industry, from R&D to technology transfer and marketing, to 
promote the development and application of emerging technologies; d) establishing 
R&D funds, providing incentives (such as favorable tax policies) to encourage 
private investment, and easing the laws on capital investment; and e) strengthening 
R&D (new technology communication), product development, and market 
internationalization. Germany presents a typical case of a government that 
aggressively promotes the biotechnology industry, which drives industry 
improvement and leads cluster cooperation. The biotechnology industry cannot act 
without interacting with other organizations, including companies, government 
agencies, universities, and research institutes. Due to the diversity of resources 
demanded in the biotechnology industry during the development process, from 
R&D to fabrication and marketing, a single enterprise cannot accomplish any step 
independently. Cluster cooperation not only promotes energy accumulation but 
also expandsthe scope of activities conducted by an enterprise. In sum, cluster 
cooperation among enterprises involves multiple areas and objects and thus 
business management ability is a crucial factor for evaluating cluster cooperation. 
3) France’s main policies to promote the biotechnology industry include the 
following: aggressively developing biological medicine and strengthening 
biotechnology R&D, easing relevant laws, and providing financial support and tax 
incentives. These measures significantly promote the rapid proliferation of 
biotechnology start-ups. In addition to fundamental studies, France focuses on the 
stimulation of industry-academy cooperation, decentralization of technological 
achievements, acceleration of internationalization, improvements in the investment 
environment, and revisions to relevant regulations. Cluster cooperation between 
enterprises has flourished under the government’s leadership and promotion. The 
associated amalgamation of capital, regulations, and the environment is an 
indispensable factor in cluster cooperation among biotechnological enterprises 
from initial R&D to technology transfer and international cooperation. Cluster 
cooperation enhances an enterprise’s professionalism and expands its network. 
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Consequently, the utilization of government resources is a crucial element in the 
evaluation of cluster cooperation. 
4) The development of China’s biotechnology industry is mainly led by the 
government and thus differs from the marketmechanism-oriented development of 
the industry in the United States. China’s development policies include anemphasis 
on scientific and technical R&D, the cultivation of flagship enterprises, 
intensification ofinternational competitiveness, encouragement of foreign 
investment and factory establishment, and strengthened administrative approval 
and supervision processes. Cluster cooperation among enterprises is conducted 
under the management and control of the government. Unlike Western countries, 
which are characterized by freeeconomies, the government in China plays a 
leadership role in scientific and technical R&D, regulation counseling, and 
internationalization. Thus, the evaluation of cluster cooperation primarily depends 
on the policy indexes. 
5) In addition to a national development strategy for the biotechnology industry, 
Japan has devised other policies, such as the jointgeneration of development 
strategies by organizations, an emphasis on fundamental research, the 
determination of major development fields, intensification of the integration of 
R&D and industry acceleration, improvements in international competitiveness, the 
cultivation of a venture capital industry, the construction of infrastructure for 
biotechnology development, the relaxation of various censorship standards, and the 
nurturing of human resources. Japan has paid close attention to R&D innovation 
and the construction of its infrastructure.  
6) Taiwan’s biotechnology industry is still considered a follower. To fill the 
critical gap in industrial development, the Taiwanese government implemented the 
Taiwan Diamond Action Plan for Biotech Takeoff. The primary aims of this plan 
are to improve the commercial energy of R&D institutions, strengthen the 
exploitation of pharmaceutical and medical devices, attract capital to the industry, 
and promote cluster formation in the biotechnology industry using integration and 
incubation mechanisms and the energy of regional industries and research 
institutes. The strategy is to transform Taiwan into an Asia-Pacific hub for the 
development of biotechnology and pharmaceutical industries. It is estimated that 
by the end of the year 2025, 20 new pharmaceuticals will be developed, 80 niche 
medical devices will be listed in overseas markets, and 10 flagship brands of 
biotechnology and health services will be created. Future promotion of Taiwan’s 
biotechnology industry will focus on the intensification of biotechnology, 
encouragement of innovative R&D, promotion of the commercialization of 
biotechnology and pharmaceutical industries, the strengthening of pharmaceutical 
administration and counseling, activation of biotechnology venture capital, and 
enhancement of incubation and cluster development. The promotion of the 
biotechnology industry emphasizes acceleration of biotechnology transfer and the 
fortification of the energy of the incubation cluster. The successful development of 
the biotechnology industry in various countries around the world shows that cluster 
cooperation plays an important role. Therefore, exploring the factors that influence 
cluster cooperation can assist in revealing the sources of development, whichmakes 
the objective of this study even more significant. 
 
2.3. Influential factors of cluster cooperation in the biotechnology 
industry 
From the early stages of R&D topic identification, enterprises within the 
biotechnology industry need to communicate with research institutes and R&D 
organizations to ensure the accuracy and feasibility of technological R&D 
standards. In the clinical test stage, enterprises mustengage in cluster cooperation 
with medical and inspection institutions to guarantee the effectiveness and 
consistency of developed products. Subsequently, at the product launch stage, 
business management requires the introduction of financial, tax, and legal support, 
intellectual property protection, and marketing to meet business development needs 
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in different stages. Cluster cooperation is generally presented in a diversified 
manner and involves research institutes, government agencies, medical institutions, 
and business management units. The influential factors of cluster cooperation in the 
biotechnology industry are described below. 
2.3.1. Enterprise innovation ability 
As indicated by Bien et al. (2014), the biotechnology industry differsfrom other 
industries and must increase the value of innovative R&D through R&D interaction 
among enterprises in the early stages, particularly under the considerations of R&D 
risk sharing and cost savings. Montalvo (2011) discovered that cluster knowledge 
innovation and transfer and intellectual property protection are the major factors 
that impact cluster cooperation. Introducing advanced R&D innovative techniques 
into the system from overseas research institutes is highly beneficial to industry 
development. The knowledge absorptive capacity and social network proliferation 
mechanisms that are involved in the process are clearly related to the growth of 
knowledge innovation capacity. Hu & Hung (2014) noted that in developing 
countries, research results -particularly innovative achievements in high-
technology industries- must be protected. Okamuro & Nishimura (2015) proposed 
that among all factors that influence the fundamental conditions for international 
cluster cooperation, the concept of innovation capacity is the most important 
andthus should be considered first in cluster cooperation. Innovation capacity, 
including R&D, technology transfer, and international cooperation, should be the 
chief priority for enterprises in cluster cooperation and can reflect the performance 
of the network. Hsu et al. (2015) found that influential factors for technology 
transfer in universities include the energy and creativity of the founder and 
entrepreneur, the experience of the entrepreneur, the social network, patent 
diversification experience, and the innovative energy of research evidence and the 
design prototype, all of which indicate that enterprises engaged in cluster 
cooperation with colleges and universities should aim to improve their internal 
creativity. In other words, enterprises can enhance R&D energy by engaging in 
cluster activities with international research institutes, which reflects the overall 
performance of their innovation capacity. 
2.3.2. Government resource utilization 
Governments tend to enhance the biotechnology industry through various 
measures taken from different perspectives, including nurturing talent, raising 
capital, assisting R&D technology, and incubating business start-ups. In this 
manner, enterprise growth is stimulated and industry development is promoted. 
Okamuro & Nishimura (2015) indicated that Germany, Japan, and France promote 
cluster cooperation through national policies. Cluster cooperation has benefitted 
from substantial privileges and subsidies from the governments of these countries 
and is clearly organized to implement their respective policies. Hsu et al. (2005) 
suggested that governments could promote and improve the overall development 
environment through various policies, such as enhancing the education system to 
foster talent, revising the operation procedures of scientific and technical R&D 
institutions, updating the information network to perfect infrastructure, directly 
participating in new product purchases, contracting for research plans, and 
indirectly setting an import tariff, to effectively influence the supply side of 
industrial innovation. Using taxation, regulations, preferential measures, and 
financial indexes, governments can impact biotechnology industry development. 
Hence, the overall development of biotechnology companies cannot be achieved 
without the use of government resources. Therefore, the use of resources provided 
by the government to enterprises pursuing certain achievements through interaction 
with others is a crucial influential factor in cluster cooperation. Government 
resource utilization can signal that an enterprise has passed the government’s 
screening mechanism and that it possesses the ability to complete tasks 
commissioned by the government, revealing – to a certain extent – its superiority 
over other enterprises. 
2.3.3. Business management ability 
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Bien et al. (2014) indicated thatthe development process is very long for both the 
biotechnology industry and biotechnology products. Moreover, most enterprises 
that need to interact with other enterprises, research institutes, and government 
departments to share risk and costsdue to limited resources are small and 
mediumenterprises. Relevant activities during such interactions include strategic 
allianceswith research institutes to ensure R&D technology transfer, vertical 
integration with upstream and downstream enterprises, and application for 
government tax benefits and R&D subsidies. In short, all internal and external 
cluster activities related to business management are encompassed by this range. 
Therefore, industrial cluster cooperation is extremely common. Limited by the fact 
that the biotechnology industry mainly comprises small and mediumenterprises, 
Taiwan lacks the resources to handle businessother than R&D. Hence, the 
Taiwanese government directly and indirectly provides incubation center services 
to the biotechnology industry to ensure that industrial requirements are met. For 
example, the Nankang Biotech Incubation Center (NBIC), which is conveniently 
located in the Nankang Software Park of Taipei, integrates the abundant 
surrounding resources, including the biotechnology center, Academia Sinica, and 
multiple large-scale teaching hospitals and research institutes in North Taiwan, to 
achieve the cluster addition effect. This center provides a good cultivating and 
counseling environment for the initiation and development of Taiwan’s 
biotechnology industry. In particular, the NBIC provides biotechnology start-ups 
with public spaces, such as clean rooms, negative-pressure rooms, 
precisioninstrument rooms, and sterile culture rooms, to satisfy the specific 
environmental requirements of biotechnology R&D. In addition, the center offers 
enterprises full access to communal facilities and equipmentto reduce the burden 
and risk of the entrepreneurial process. With the accumulation of the energies 
mentioned above, enterprises can gradually strengthen their internal business 
management energy, which differs from that of non-biotechnology industries. This 
internal business management energy plays a critical role in the business of future 
start-ups and is an important factor in cluster cooperation. 
2.3.4. Mutual trust 
Cooke et al. (1997) suggested that learning, trust, dependence, exchange, and 
internal cooperation are crucial factors in the innovation system that exists between 
regions. This system is generally conducted through regional integration associated 
with certain cultural foundations in a particular region. Bien et al. (2014) indicated 
that during the process of knowledge exchange and resource sharing, R&D 
companies are often at risk of leaks or theft of confidential information. Therefore, 
mutual trust between partners has become a significant topic in cluster cooperation. 
In the past decade, the importance of R&D cooperation between enterprises has 
escalated, particularly for innovation in technology-intensive fields such as the 
biotechnology industry. The pursuit of borderless innovation has become an 
important strategy for maintaining a competitive advantage in this industry. R&D 
cooperation is regarded as a major means of obtaining crucial resources for 
enterprises because it not only reduces R&D costs through risk sharing but also 
helps enterprises to acquire necessary technical information and to improve R&D 
efficiency through information exchanges with different organizations. Compared 
to other industries, the biotechnology industry relies more on R&D cooperation due 
to long development cycles and the enormous costs associated with its inherent 
high-risk nature and its knowledge- and capital-intensive characteristics. Therefore, 
effective approaches for gaining external resources have become crucial for the 
survival of the biotechnology industry, leading to a general trend of technical 
cooperation among enterprises and organizations. Mutual trust is critical for 
smooth cooperation, which is reflected through mutual communication and 
interaction andadded value sharing. Successful cooperation will eliminate distrust, 
and mutual trust between organizations will increase the flexibility of cooperation 
between them. Mutual trust is universally established through acquaintances and 
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interactionsassociated with R&D cooperation, including exclusive authorizations, 
formal contracts, and informal communications.  
In summary, enterprise innovation ability, government resource utilization, 
business management ability, and mutual trust are the most crucial factors for the 
success of Taiwan’s biotechnology industry and thus are the major focus of this 
study.  
 
3. Research methods 
3.1. Research framework 
The structure for the initial stage of this study is established based on the 
literature discussed in Section 2, and the operative definitions of various factors are 
explained in this section. The overall dimension is divided into four sub-
dimensions that reflect the influential factors of cluster cooperation in Taiwan’s 
biotechnology industry, namely, enterprise innovation ability, government resource 
utilization, business management ability, and mutual trust. Enterprise innovation 
ability includes four sub-dimensions: number of patents (intellectual property), 
R&D personnel qualities, R&D environment, and R&D network. Government 
resource utilization encompasses talent training, research technology transfer 
mechanisms, R&D incentive measures, and business incubation and counseling. 
Business management ability contains three sub-dimensions: degree of 
internationalization, intellectual property management flexibility, and financial 
improvement capacity. Mutual trust comprises three parts, namely, corporate 
culture, executive capacity, and cooperation network. Figure 1 shows the research 
framework of the first stage.  
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Figure 1. First-stage hierarchy framework 
 
3.2.  Expert interviews 
To explore the influential factors of cluster cooperation in Taiwan’s 
biotechnology industry, expert interviews are conducted based on the factors 
obtained from the framework literature in Section 3.1 in order to determine the 
applicability of the crucial factors and adjust them within the framework. The 
expert interviews are described in detail below. First, the companies to be 
interviewed are introduced. 
3.2.1. Company A 
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Established in 2002, Company A is an OTC (over-the-counter)-based company 
engaged in new drug R&D. This company’s priority is to meet unsatisfied medical 
demands in the fields of anti-cancer and anti-infection pharmaceutical 
development. Its primary approach to obtain technical sources is cluster 
cooperation with international research institutes that possess progressive 
technologies. Company A has a high-level business management team, a 
commendable overall management energy, and an anticipated niche. Based on its 
own experience, the company suggests that a high-level business management 
team should be included as a subsequent layer of business management ability in 
this research framework because it is considered one of the most crucial sub-
factors. 
3.2.2. Company B 
Company B was founded in 1993 and subsequently listed. This companyfocuses 
primarily on developing new pharmaceuticals, improving biotechnology standards, 
and producing high-quality drugs at reasonable prices in the international market. 
Company B strongly agrees with the inclusion of the degree of internationalization 
as a sub-factor in the business management ability dimension of cluster 
cooperation. 
3.2.3. Company C 
Established in 2013, Company C devotes itself to the development of 
technologies for innovative antibody drugs. Cooperating with multiple industry-
education organizations, this company has produced new antibody drugs and 
entered the global market. Company C strongly agrees that enterprise innovation 
ability is the most important influential factor for cluster cooperation in Taiwan’s 
biotechnology industry and emphasizes that enterprise R&D personnel qualities are 
the touchstone of an enterprise’s innovation ability. 
3.2.4.Company D 
Founded 13 years ago, Company D mainly provides services to the 
biotechnology industry by accepting commissions to conduct research on 
toxicology, pathology, and simple pharmacology. It has experimental animal rooms 
for studies on toxicity and sub-acute, acute, and functional dietary supplements. In 
the value chain of biotechnology industry development, Company D belongs to the 
service industry for pre-clinical tests. Based on its experience with business 
management, Company D believes that government resource utilization is the 
dominant determinant of an enterprise’s development environment and of the range 
and depth of its cluster cooperation. 
3.2.5.Company E 
Company E works with natural minerals, which are nanonized using advanced 
technologies in the R&D of biotechnology products and drug delivery platforms, 
and focuses on anti-cancer drugs for restraining disease development. It expects to 
provide more efficient and safe medicines to patients, improving their quality of 
life. The company maintains that mutual trust is a significant factor in cluster 
cooperation with international enterprises. 
3.2.6.Organization F  
Established in 1996, Organization F executes and promotes policies for 
biotechnology industry development and acts as a bridge for communication, 
coordination, and integration among departments to construct a complete 
development environment for the biotechnology industry. This organization 
provides orientation for Taiwan’s biotechnology industry development, facilitates 
international interactions in the industry, and operates as a mediator and 
coordinator of cluster cooperation. Organization F emphasizes that global vision is 
imperative in industrial cluster cooperation and that Taiwan’s biotechnology 
industry should aggressively target the international market for both R&D and 
listing. 
3.2.7.Organization G 
Organization G focuses mainly on generating a superior cultivation 
environment and promoting biotechnology incubation policies through the efficient 
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integration of multiple types of resources, including spaces, instruments and 
equipment; R&D techniques; fundraising; business services; and management 
counseling. To improve the cluster cooperation environment of the biotechnology 
industry, this organization provides necessary assistance to enterprises, helping 
them to meet the periodic requirements of biotech enterprise management. 
3.2.8.University H 
University H is a distinguished university established in 1976 in Taipei and 
comprises a medical university and an affiliated hospital. The medical university 
attaches great importance to the transfer of research technology and is very positive 
about interacting with enterprises, research institutes, and hospitals. In addition, 
University Hpossesses abundant practical experience in cluster cooperation 
between upstream and downstream organizations. 
3.2.9.Organization I 
Organization I is a non-profit organization that was established through 
government and public donations in 1984. It aims to construct the necessary 
environment and infrastructure for the development of Taiwan’s biotechnology 
industry by developing critical biotechnology and fostering and recruiting 
professional talent through cooperation with enterprises, the government, 
universities, and research institutes. 
 
Table 2. Information about interviewed experts 
Interviewed company Seniority Title 
Company A 28yrs President 
Company B 25yrs General manager 
Company C 25yrs General manager 
Company D 25 yrs General manager 
Company E 25yrs Deputy general manager 
OrganizationF 18 yrs Senior manager 
OrganizationG 15yrs Senior manager 
UniversityH 20yrs Dean 
Organization I 25yrs Director 
 
The results of the expert interviews reveal that experts hold differing opinions 
on the utilization of government resources but agree that the biotechnology 
industry requiresextensive involvement in laws and regulations. Enterprises must 
adhere to various laws and regulations from the early stages of product 
development for R&D security. However, the government must offer counseling 
services to enterprises at each stage of R&D and manufacturing in order to promote 
industrial development. Therefore, the utilization of government resources in the 
form of regulatory counseling is an important sub-factor that impacts cluster 
cooperation among biotechnology enterprises. Moreover, regarding the business 
management ability factor, the experts believe that the experience and performance 
of a high-level business management team significantly influence an enterprise’s 
long-term positioning and business model and thus constitute a major sub-factor of 
business management. The expert interview results show that two factors described 
above (government resource utilization and business management ability) are 
influential in cluster cooperation in Taiwan’s biotechnology industry. The research 
framework proposed above is revised accordingly and presented as Figure 2. 
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Information disclosure 
Influential 
factors of 
cluster 
cooperation 
in Taiwan’s 
biotechnology 
industry 
Enterprise 
innovation ability 
Government 
resource 
utilization 
Business 
management 
ability 
Number of patents 
(intellectual property) 
R&D personnel qualities 
R&D environment 
 
R&D network 
 
Talent training 
 
R&D incentive measures 
Business incubation and 
counseling 
 
Internationalization 
degree 
Intellectual property 
management flexibility 
Financial improvement 
capacity 
Research technology 
transfer mechanism 
Mutual trust 
 
Corporate culture 
 
Executive capacity 
 
Cooperation network 
High-level business 
management team 
Regulatory counseling 
 
Figure 2. Second-stage hierarchy framework 
 
Table 3 presents the operative definitions of influential factors in cluster 
cooperation in Taiwan’s biotechnology industry. 
 
Table 3. Operative definitions of influential factors incluster cooperation in Taiwan’s 
biotechnology industry 
Influential factors in cluster cooperation in T
aiw
an’s biotechnology industry 
E
nterprise innovation 
ability      
Number of patents 
(intellectual 
property) 
The number of patents for which an enterprise applies to improve the technical 
distribution. 
R&D personnel 
qualities 
Education and experience of relevant R&D personnel within an enterprise 
(Huang et al., 2010). 
R&D environment Software and hardware environments associated with R&D activities within an 
enterprise (Subramaniam & Youndt, 2005). 
R&D network Operation of tangible and intangible networks for R&D cooperation within 
and outside an enterprise (Drejer & Jorgensen, 2005). 
G
overnm
ent resource 
utilization 
Talent training Training (organized by the government) of the talent to promote industry 
development and reduce academy-industry disparities.  
Research technology 
transfer mechanism 
Measures implemented by the government to smoothly transfer R&D 
achievements from universities and research institutes to enterprises for 
efficient application. 
R&D incentive 
measures 
Preferential measures implemented by the government to stimulate and 
promote industrial R&D (Bien et al., 2014). 
Business incubation 
and counseling 
Entrepreneurship incubation and business management counseling provided 
by the government to promote industrial development. 
Regulatory 
counseling 
Regulatory assistance provided by the government to help an enterprise meet 
requirements in different stages of biotechnology industrial development 
(Ernst & Young, 2016). 
B
usiness m
anagem
ent 
ability 
High-level business 
management team 
Executive officers responsible for an enterprise’s overall business 
management (Downs & Velamuri, 2016). 
Internationalization 
degree 
Degree to which an enterprise is valued worldwide by people in the same 
business during the process between R&D and marketing (Feldman & Francis, 
2014). 
Intellectual property 
management 
flexibility 
Flexibility of an enterprise’s management tomaximize the benefits of 
intellectual property (Su & Hung, 2009). 
Financial 
improvement 
capacity 
Capacity of an enterprise’s management to improve the financial system for 
sustainable development (Rosson & Mclarney, 2005). 
Mutual 
trust 
Corporate culture Traits of an enterprise’s internal activities (Trippl et al., 2007). 
Executive capacity Capacity to negotiate operating standards and managerial agreement during 
cluster cooperation between enterprises (Edquist, 2005). 
Cooperation 
network 
Correlation between enterprises in cooperation (Todtling, & Lehnei, 2006). 
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3.3. Analytic hierarchy process  
AHP is a method used to simplify complex problems of elemental hierarchy. 
Furthermore, based on the opinions of experts and decision makers for each layer, 
a pairwise comparison matrix is constructed using the quantified results of the 
pairwise comparison between the executed elements and a nominal scale. Based on 
the eigenvector of each matrix and the priority order of the elements in the layers 
(eigenvectors), the maximum eigenvalue is calculated to evaluate the relative 
weight of coincident indicator (CI) of the comparison matrix, which provides a 
reference for decision makers. Generally conducted on a hierarchy with at least 
three layers, AHP connects all of the layers to calculate the CI and the 
conformance rate (CR) of the pairwise comparison matrix of the elements between 
the layers. The results are used to evaluate the consistency of the overall hierarchy. 
Therefore, in AHP, experts’ suggestions are adopted to solve complicated decision-
making problems and the comparison matrix and eigenvector are applied to 
determine relativeweight-associated problems that impact elements between the 
layers (Saaty, 1980). 
3.4. Research objects and data collection method 
The research objects of this study include a number of entities in Taiwan’s 
biotechnology industry. A questionnaire survey is conducted on senior(five+ 
years), middle and topmanagers of enterprises, the government, universities, and 
research institutes in the biotechnology industry. Completed questionnaires are 
collected in paper form and by email without disclosing the managers’ names. 
During the survey, the investigation objective and questionnaire content are 
presented to the interviewed experts to guarantee the validity and recovery rate of 
the questionnaires. In the questionnaires that are designed to collect experts’ ideas, 
five evaluation measures of AHP are set on a nine-layer hierarchy, namely, equally 
important, slightly important, very important, extremely important, and absolutely 
important, as shown in Table 4. 
 
Table 4.  Evaluation measures 
Evaluation 
measure 
Definition Instructions 
1 Equally important Contributions of two indicators are of equal 
importance – equally important. 
2 Evaluation measure is between 1 and 3 Compromised value is between the evaluation 
measures 1 and 3. 
3 Slightly important Slightly inclined toward a certain scheme based on 
experience and judgment – slightly important. 
4 Evaluation measure is between 3 and 5 Compromised value is between 3 and 5. 
5 Very important Fairly inclined toward a certain scheme based on 
experience and judgment – very important. 
6 Evaluation measure is between 5 and 7 Compromised value is between 5 and 7. 
7 Extremely important Strongly inclined toward a certain scheme in practice 
– extremely important. 
8 Evaluation measure is between 7 and 9 Compromised value is between 7 and 9. 
9 Absolutely important An indicator is sufficiently proved to be important – 
absolutely important. 
Data source: Zhengyuan Deng, Guoxiong Zeng (1989). 
 
4. Research results 
In this study, an investigation is conducted using AHP by collecting 
questionnaire responses from executive managers and experts in the biotechnology 
industry. Based on the results, the weights of various factors are statistically 
obtained. Thus, the research results can be deduced based on the influential degree 
of each factor’s weight. 
4.1. Basic information obtained through questionnaires 
In this study, 25 questionnaires are sent to the research objects, including 
executive managers and experts in Taiwan’s biotechnology industry. Twenty 
usable responses are collected from the 21 recovered responses, for a recovery rate 
of 80%, as presented in Table 5. Regarding service seniority, managers with 
seniority between five and 10 years, between 11 and 15 years, and greater than 15 
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years account for 35%, 40%, and 25% of respondents, respectively (Table 6). Table 
7 provides an overview of experts’ titles. 
 
Table 5. Summary of questionnaire collection 
Questionnaire information Sample number Percentage 
Distributed questionnaires 25 100% 
Recovered questionnaires 21 84% 
Invalid questionnaires 1 4% 
Valid questionnaires 20 80% 
 
Table 6. Service seniority of interviewed experts 
Service seniority Sample number Percentage 
5-10 yrs 7 35% 
11-15 yrs 8 40% 
>15 yrs 5 25% 
Total 20 100% 
 
Table 7. Expert titles 
Affiliated enterprise or organization Title 
A Governmental industry-promotion organization 1 Senior manager Yang 
B Governmental industry-incubation organization 2 Manager Chen 
C Governmental organization 3 Team leader Chung 
D Governmental organization 4 Section chief Lin 
E Governmental organization 5 Section chief Lin 
F Legal entity 1 Manager Juan 
G Legal entity 2 Manager Lin 
H Legal entity 3 Deputy manager Gao 
I Legal entity 4 Senior associate researcher Tsai 
J Legal entity 5 Researcher Chiang 
K Biotech pharmaceutical factory 1 Manager Gao 
L Biotech pharmaceutical factory 2 Manager Gao 
M Biotech pharmaceutical factory 3 Deputy manager Lai 
N Biotech pharmaceutical factory 4 Deputy manager Shih 
O Biotech pharmaceutical factory 5 Manager Chang 
P University professor 1 
Q University professor 2 
R University professor 3 
Professor Lan   
Professor Wu     
Professor Chen  
S University professor 4 Professor Hsu 
T University doctoral student 5 Student Wang 
 
4.2. AHP results 
In this study, “Expert Choice 2000” software is used as the AHP tool to 
calculate the weight of each influential factor in cluster cooperation. The AHP 
expert questionnaire presented in Table 8 provides statistical data for each factor’s 
weight. The overall weight (priority weight) is relative to the product of primary 
and secondary dimensions. The order of the dimensions can be obtained from the 
magnitude of the overall weights. 
 
Table 8. Weight analysis of each dimension using AHP 
Primary dimension Secondary dimension Overall weight Ranking 
 Number of patents (intellectual property) 0.086884 3 
Enterprise innovation 
ability 0.428 
R&D personnel qualities 0.171628 1 
R&D environment 0.092448 2 
 R&D network 0.076612 5 
 Talent training 0.02511 15 
Government resource 
utilization 0.155 
Research technology transfer mechanism 0.0599 16 
R&D incentive measures 0.036425 12 
 Business incubation and counseling 0.038905 11 
 Regulatory counseling 0.035185 14 
 High-level business management team 0.07367 6 
Business management 
ability 
Internationalization degree 0.053098 9 
Intellectual property management flexibility 0.065608 7 
0.278 Financial improvement capacity 0.085624 4 
 Corporate culture 0.041283 10 
Mutual trust Executive capacity 0.061438 8 
0.139 Cooperation network 0.036279 13 
 
To discuss the weight of the primary dimensions of influential factors, namely, 
enterprise innovation ability, government resource utilization, business 
management ability, and mutual trust, the weights and ranking of the four primary 
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dimensions must be calculated using the statistical results of the AHP expert 
questionnaires. Table 9 shows the pairwise comparison matrix and CI of the four 
dimensions. 
 
Table 9. Pairwise comparison matrix of the primary dimensions 
 Enterprise 
innovation ability 
Government 
resource 
utilization 
Business 
management 
ability 
Mutual trust Overall 
weight 
Ranking 
Enterprise 
innovation ability 
1 3.217994 1.879443 2.131081 0.428 1 
Government 
resource utilization 
0.310753 1 0.577114 1.300954 0.155 3 
Business 
management ability 
0.532073 1.732761 1 2.557109 0.278 2 
Mutual trust 0.469246 0.768667 0.391067 1 0.139 4 
 
In the framework of influential factors for cluster cooperation in Taiwan’s 
biotechnology industry, theresults of this research indicate that the top layer 
includes enterprise innovation ability, government resource utilization, business 
management ability, and mutual trust. Enterprise innovation ability has the greatest 
weight, followed by business management ability and government resource 
utilization, whereas mutual trust has the lowest weight among the four factors. As 
shown by the results, enterprise innovation ability is the most important influential 
factor in cluster cooperation in the current biotechnology industry. Enterprise 
innovation ability and business management ability are the main forces behind 
biotechnology activities and reflect the primary characteristics of R&D innovation 
and business models in the biotechnology industry. Government resource 
utilization also has certain effects on the development of the biotechnology 
industry, particularly for biotechnology start-ups, whose growth from R&D to 
commercialization depends heavily on government assistance for cost savings and 
to accelerate commercialization. Hence, government resource utilization is an 
essential factor in cluster cooperation. Moreover, mutual trust plays an 
indispensable role in integrating the relevant factors and improving the efficiency 
of cluster cooperation in Taiwan’s biotechnology industry. 
Secondary dimension analysis involves various sub-factors of the four primary 
dimensions of enterprise innovation ability, government resource utilization, 
business management ability, and mutual trust. 
1) Weight and ranking analysis of influential factors under the primary 
dimension of enterprise innovation ability 
There are four sub-factors under the primary dimension of enterprise innovation 
ability: number of patents (intellectual property), R&D personnel qualities, R&D 
environment, and R&D network. Table 10 presents the pairwise comparison matrix 
and weight ranking of the sub-factors of enterprise innovation ability. 
 
Table 10.  Pairwise comparison matrix of the secondary dimensions 
 
 Number of 
patents 
(intellectual 
property) 
R&D personnel 
qualities 
R&D 
environment 
R&D network Hierarchical 
weight 
Overall 
weight 
Ranking 
Number of patents 
(intellectual 
property) 
1 0.66052301 1.0344285 0.793835014 0.203 0.086884 3 
R&D personnel 
qualities 
1.5139518 1 2.4555006 2.2790256 0.401 0.171628 1 
R&D environment 0.966717371 0.407248933 1 1.7376689 0.216 0.092448 2 
R&D network 1.2597076 0.438784014 0.575483626 1 0.179 0.076612 4 
 
  
The results reveal that R&D personnel qualities, with a weight of 0.401, 
significantly impact enterprise innovation ability, followed by R&D environment 
and number of patents (intellectual property), with weights of 0.216 and 0.203, 
respectively. R&D network, with a weight of only 0.179, impacts enterprise 
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innovation ability the least. Under the dimension of enterprise innovation ability, 
R&D personnel qualities and R&D environment are the most crucial factors 
because biotechnology enterprises are R&D-oriented organizations in which 
personnel qualities constitute the critical capital of enterprise creativity and an 
optimal innovation environment allows biotechnology R&D personnel to perform 
to their maximum potential and create greater cluster benefits. Regarding the 
number of patents (intellectual property) and R&D network, the former represents 
enterprise innovation capacity, which can encourage enterprise creativity, whereas 
the latter reflects the communication and sharing of R&D information, which 
contributes to enterprise innovation to a certain extent. 
2) Weight and ranking analysis of influential factors under the primary 
dimension of government resource utilization 
The primary dimension of government resource utilization includes five 
influential sub-factors, namely, talent training, research technology transfer 
mechanism, R&D incentive measures, business incubation and counseling, and 
regulatory counseling. Table 11 presents the pairwise comparison matrix and 
weight ranking of the influential sub-factors under government resource utilization. 
 
Table 11. Pairwise comparison matrix of the secondary dimensions 
 Talent 
training 
Research 
Technolog
y 
Transfer 
mechanis
m 
R&D 
Incentive 
measures 
Business 
incubation and 
counseling 
Regulatory 
counseling 
Hierarchical 
weight  
Overall 
weight
  
Ranking 
 
Talent training 1 1.1875085 0.866313528 0.61378609 0.639843776 0.162 0.02511 4 
Research technology 
transfer mechanism 
0.842099236 1 0.527325924 0.465059282 0.553954719 0.125 0.019375 5 
R&D incentive measures 1.1543165 1.8963604 1 1.1125274 1.0646415 0.235 0.036425 2 
Business incubation and 
counseling 
1.6292321 2.1502635 0.898854266 1 1.1791476 0.251 0.038905 1 
Regulatory counseling 1.5628815 1.8052017 0.939283317 0.84807025 1 0.227 0.035185 3 
 
The results indicate that business incubation and counseling, with a weight of 
0.251, is the most important influential factor in government resource utilization, 
followed by R&D incentive measures and regulatory counseling, with weights of 
0.235 and 0.227, respectively. Research technology transfer mechanism, with a 
weight of 0.162, has the lowest impact among these four sub-factors. In the 
dimension of government resource utilization, business incubation and counseling 
has the highest weight because the biotechnology industry is composed mainly of 
R&D-oriented mediumand small enterprises whose growth -from early R&D to 
technology commercialization- depends on the government’s incubation and 
counseling and involves patents, laws and regulations, finance, and accounting. 
R&D incentive measures and regulatory counseling are of secondary importance, 
because biotechnology is closely associated with people’s health and well-being 
and thus is under intense legal and regulatory supervision. The government usually 
provides biotechnology enterprises more assistance in the areas of R&D, 
manufacture, commercialization, and finance through regulations. The low weights 
of the sub-factorstalent training and research technology transfer mechanism are 
due to the diversification of the involved fields/organizations and varying levels of 
emphasis on schools and industrial organizations. In particular, the enterprise’s 
techniques are not obtained only from academic communities and talent training is 
not provided entirely by the government.  
3) Weight and ranking analysis of influential factors under the primary 
dimension of business management ability 
There are four influential sub-factors under business management ability: high-
level business management team, degree of internationalization, intellectual 
property management flexibility, and financial improvement capacity. Table 12 
shows the pairwise comparison matrix and weight ranking of the sub-factors under 
business management ability. 
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Table 12. Pairwise comparison matrix of the secondary dimensions 
 High-level 
business 
management 
team 
Internatio
nalization 
degree 
Intellectual 
property 
management 
flexibility 
Financial 
improvement 
capacity 
Hierarchical 
weight 
Overall 
weight 
Ranking 
High-level business management team 1 1.1131557 1.3931514 0.869113505 0.265 0.07367 2 
Internationalization degree 0.898346925 
 
1 0.593114569 
 
0.669416182 
 
0.191 
 
0.053098 
 
4 
Intellectual property management 
flexibility 
0.717797075 1.6860149 1 0.670783893 0.236 0.065608 3 
Financial improvement capacity 1.1505977 1.493839 1.4907931 1 0.308 0.085624 1 
 
The results show that financial improvement capacity, with a weight of 0.308, is 
the most important sub-factor in the primary dimension of business management 
ability, followed by high-level business management team and intellectual property 
management flexibility, withweights of 0.265 and 0.236, respectively. The least 
important sub-factor under business management ability is the degree of 
internationalization, with a weight of 0.191. Financial improvement capacity and 
high-level business management team have the highest weights, which can be 
explained by the significant focus of the biotechnology industry on R&D and the 
fact that the process of developing a new drug from R&D to commercialization is 
very long (a ten-year development period for a drug is typical) and includes three 
phases of clinical trials, which require significant capital support. Therefore, sound 
finance is a prerequisite for an enterprise’s existence and a critical sub-factor in 
cluster cooperation. A high–level business management team with good techniques 
and a background in international business management is essential for enterprise 
development, owing to the impact of the business management team on the fate of 
the enterprise. In contrast, intellectual property management flexibility and the 
degree of internationalization are strategies adopted by enterprises based on their 
development. 
4) Weight and ranking analysis of influential factors under the primary 
dimension of mutual trust. 
Under the primary dimension of mutual trust, there are three sub-factors, 
namely, corporate culture, executive capacity, and cooperation network. Table 13 
presents the pairwise comparison matrix and weight ranking of the influential sub-
factors under mutual trust. 
 
Table 13. Pairwise comparison matrix of the secondary dimensions 
 Corporate 
culture 
Executive 
capacity 
Cooperation 
network 
Hierarchical 
weight 
Overall 
weight 
Ranking 
Corporate culture 1 0.700519456 1.09284 0.297 0.041283 2 
Executive capacity 1.4275121 1 1.7592499 0.442 0.061438 1 
Cooperation network 0.915047033 0.568424077 1 0.261 0.036279 3 
 
The research results reveal that executive capacity, with a weight of 0.442, is 
the most influential factor in mutual trust, followed by corporate culture and 
cooperation network, with weights of 0.297 and 0.261, respectively. Executive 
capacity has the largest weight because it is the key to quality during technique and 
product development, which is guided by relevant operational manuals and 
standard operating procedures. Mutual trust between enterprises and a corporate 
culture based on entrepreneurship could promote harmony in cluster cooperation 
and generate comprehensive effects. The cooperation network is a reflection of 
mutual trust. 
 
5.Conclusions and recommendations 
In this study, the influential factors of cluster cooperation in Taiwan’s 
biotechnology industry are discussed. To identify the critical factors, in-depth 
expert interviews and an AHP expert questionnaire analysis were conducted in the 
first and second stages, respectively. Based on the continuously growing 
biotechnology industry in Taiwan, experts in companies, the government, 
universities, and research institutes proposed key factors in cluster cooperation in 
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the biotechnology industry, indicating that development of this industry depends 
mainly on the enhancement of enterprise innovation ability, business management 
ability, government resource utilization and mutual trust among enterprises. The 
research results make the content of enterprise cluster cooperation more transparent 
and clarify the energy required for cluster cooperation. The results suggest that 
government resource utilization should be better managed and that mutual trust 
among the government, enterprises, universities, and research institutes should be 
assigned greater value. The situation in Taiwan is similar to biotechnology industry 
development in Euro-American countries, where enterprises played the role of 
pioneers and governments provided appropriate support to enterprises during the 
later stages. All countries around the world must understand the essence of 
innovation and the capacity to break through existing boundaries using appropriate 
connections, which is particularly important in the biotechnology industry. 
Taiwan’s biotechnology industry may be in the critical flourishing stage, when 
enterprise innovation and flexible management are more significant than 
government resource utilization and mutual trust among enterprises. This phase 
demonstrates that Taiwan’s biotechnology industry is moving out of the initial 
developing stage and into a new stage of rapid growth. 
The influential factors of cluster cooperation in Taiwan’s biotechnology 
industry are explored from the perspectives of various roles in different 
organizations, including enterprises, the government, universities, and research 
institutes. The domestic industrial situation is introduced and major schemes to 
promote industrial development in overseas countries are described to present a 
range of industrial cluster activities. The results indicate that enterprise innovation 
ability, government resource utilization, business management ability, and mutual 
trust are the critical factors that affect cluster cooperation in Taiwan’s 
biotechnology industry. Among these factors, enterprise innovation ability has the 
greatest impact on enterprise participation in cluster cooperation, followed by 
business management ability. Accepting the government’s resources and 
strengthening mutual trust in cluster cooperation are also crucial for achieving 
comprehensive efficiency. The explanation is as follows: 
5.1.Enterprise innovation ability 
This study reveals that enterprise innovation ability is affected primarily by the 
number of patents (intellectual property), R&D personnel qualities, R&D 
environment, and R&D network. Because innovation is the lifeline of 
biotechnology enterprises, such enterprises have fairly high standards for R&D 
personnel qualities and pay close attention to in-service training. In the R&D 
environment, enterprises cannot determine facts and interpret rationality using rigid 
thoughts; thus, they must adopt more flexible measurement scales and avoid paying 
too much attention to minor details. In addition, enterprises must accept R&D risks 
and different opinions in a deliberate manner to avoid stifling creative ideas. An 
R&D network involves both hardware and software, with the latter referring to 
extensive connections to educational and research institutes in relevant technical 
fields for cluster cooperation and conference participation. Regarding technical 
achievements, enterprises must apply for patents, which are generally regarded as 
an indicator of enterprise innovation and the basis for judgment by the potential 
market, to protect their intellectual property. 
5.2. Government resource utilization 
Research indicates that government resource utilization involves talent training 
managed by the government, research technology transfer mechanisms, R&D 
incentive measures, business incubation and counseling, and regulatory counseling. 
Because enterprises pay great attention to personnel qualities, the government 
provides on-the-job and professional training to improve the quality of personnel. 
The course content for such training involves not only the relevant technical fields 
but also business management, which itself includes laws, accounting, finance, and 
intellectual property. Training provided by the government has substantially 
reduced the operating costs of enterprises. To intensify the energy of enterprises to 
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identify R&D topics and to transfer research and technical achievements, the 
government plays a mediator role to accelerate R&D, helping enterprises to obtain 
the required technical energy and to accelerate the R&D process. To encourage 
R&D innovation by enterprises, the government should provide related capital 
support for talent training and favorable tax treatment of enterprise income. For 
example, regarding the stock owned by the managers of an enterprise, the 
government can calculatethe tax based on the market price when the stock is 
transferred. Biotechnology start-ups are generally active in accessing the various 
services provided by the government, including incubation counseling, space and 
entering, raising capital, technology alliances, business opportunity matching, and 
the acquisition of market information. Even powerful and deep-pocketed 
biotechnology enterprises are fairly eager to participate in the formulation and 
modification of regulations, making these topics important to cluster cooperation. 
The use of government resources provides significant business energy to 
enterprises. 
5.3. Business management ability 
One characteristic of the biotechnology industry is innovative R&D. Hence, 
promoting innovative R&D through business management is a major activity. 
Promoting innovative R&D requires raising sufficient R&D funds, which leads to 
different management patterns. For example, when the product development of a 
biotechnology enterprise reaches a certain stage without mature products, the 
enterprise can transfer the technology to other companies through technology 
licensing for a premium. Therefore, the benefits of the biotechnology industry 
include not only production value but also technology transfer, which is very 
common in this industry. An enterprise’s need for capital is also very important. 
Enterprises often find themselves with insufficient funds to cover R&D expenses, 
which compels them to find other sources of financing, such as thedevelopment of 
biotechnology dietary supplements, to accelerate their cash flow to support new 
pharmaceutical R&D. This is a different business model that requires a different 
business management energy. Because the biotechnology industry is closely 
associated with people’s health and well-being, Taiwan’s laws and regulations on 
pharmaceutical development are relatively strict. The regulations must comply with 
international conventions, such as the inspections required by the pharmaceutical 
approval agency in the United States. Moreover, the intellectual property of 
biotechnology enterprises must be protected against infringement by international 
companies in the same industry. Therefore, the selection of R&D topics in the early 
stages must be undertaken with great caution. Patent searches and arrangements 
and compliance with technical regulations are a test of an enterprise’s business 
management energy. To gain access to corresponding incentive measures provided 
by the government, the business management process should focus on relevant 
financial and accounting operations, R&D plan writing, personnel training, and 
participation in international exhibitions and conventions. During the in-depth 
expert interviews conducted in this study, the senior experts in the biotechnology 
industry agreed that the activities mentioned above reflect an enterprise’s business 
management capacity, which is crucial for biotechnology cluster cooperation. 
These expertsmaintained that further improvements in Taiwan’s biotechnology 
industry are necessary to achieve the internationalization of business management 
energy and thatthe experience and global vision of high-level business management 
teamsare key factors in this endeavor. 
5.4.Mutual trust 
Cluster cooperation and communication among enterprises, which are common 
methods used by enterprises to pursue innovative R&D, require mutual trust as a 
core value of corporate culture. Rather thanwritten contracts that specify executive 
details, cooperation within an enterprise and between enterprises (even 
internationally) depend on corporate culture. A network based on mutual trust is 
expected to achieve incremental effects of cluster cooperation. 
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In this study, influential factors of cluster cooperation in Taiwan’s 
biotechnology industry are discussed. Due to the lack of successfully launched new 
pharmaceutical products during the present development period, market-oriented 
correlation is not explored as an influential factor in this research. Rather, this 
study investigates the relevance of influential factors in cluster cooperation in the 
biotechnology industry without making any suggestions regarding external market-
oriented requirements. Such requirements could be considered in future researchto 
identify the differences between these two perspectives. 
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